Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

BACKGROUND: The response rate of the first-line therapy with corticosteroid for acute graft versus host disease (aGVHD) is about 50%, and steroid-refractory disease is associated with high mortality. The improved response rate to the first-line therapy of newly diagnosed aGVHD patients would result...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Liping, Peng, Bo, Li, Xin, Wang, Lu, Jia, Mingyu, Xu, Lingmin, Li, Fei, Liu, Daihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169300/
https://www.ncbi.nlm.nih.gov/pubmed/35668528
http://dx.doi.org/10.1186/s13063-022-06426-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169300/
https://www.ncbi.nlm.nih.gov/pubmed/35668528
http://dx.doi.org/10.1186/s13063-022-06426-2

Ejemplares similares